Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
19/03/2014

Foto2

 

Description 

A phase 3 Randomized, doubled masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTA (anti-PDGF-b pegylated aptamer) administered in combination with Lucentis compared to Lucentis Monotherpahy in subjects with subfoveal neovascular age-related macular degeneration.

Objectives

The objectives of the study are to evaluate the safety and efficacy of FOVISTA in combination with ranibizumab (Lucentis) as compared to ranibizumab monotherapy in patients with neovascular age-related macular degeneration who have not received previous treatment.

5471__MG_8270red (1)


If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 

Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

 

 

Injections intravitréennesDMLA exsudative ou humide

Author

Dr Jordi Monés, médecin, titulaire d’un doctorat
Inscrit à l'ordre des médecins de Barcelone, sous le numéro 22838
Directeur
Docteur en médecine et chirurgie
Spécialiste en ophtalmologie
Spécialiste de la rétine, de la macula et du vitré

Last modified: 11 June, 2019 - 8:44